Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

“FDA has not yet developed action plans to fully address travel, workload, and work-life balance because potential solutions ...

Ascend Advanced Therapies, which has been on an expansion tear since debuting three years ago, inked a deal with EW ...

A strand of Merz Pharmaceuticals’ star-studded promotion of the anti-wrinkle drug Xeomin has landed it a reprimand from the ...

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...